<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">Last, patients with underlying cardiovascular disease are more likely to be infected with SARS-CoV-2, are more likely to develop severe symptoms, if infected with SARS-CoV-2, and may also be more vulnerable to adverse cardiotoxic effects of treatment with antiviral drugs. A most recent analysis from the LEOSS registry [
 <xref ref-type="bibr" rid="CR12">12</xref>] displaying the prevalence of co-morbidities in COVID-19 patients in Germany disclosed that in all classes of disease severity more than 50% of the patients suffered from cardiovascular co-morbidity, which was by far the most prominent co-morbidity associated with COVID-19 (Fig.Â 
 <xref rid="Fig2" ref-type="fig">2</xref>).
</p>
